Editas gets FDA rare pediatric disease status for gene-edited drug EDIT-301 for beta thalassemia

Grandbrothers/iStock Editorial via Getty Images

• The U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation to Editas Medicine's (NASDAQ:EDIT) gene-edited medicine EDIT-301 to treat beta thalassemia, an inherited blood disorder.
• The company said it expects to begin